Seretide Description

Inhaler: Each single actuation of SERETIDE provides: Salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 50 or 125 micrograms of fluticasone propionate.
SERETIDE Inhaler comprises a suspension of salmeterol and fluticasone propionate in the non-CFC propellant HFA 134a. The suspension is contained in an aluminium alloy can sealed with a metering valve. The canisters are fitted into plastic actuators incorporating an atomising orifice and fitted with dustcaps.
Diskus: Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 micrograms of salmeterol as salmeterol xinafoate and 100 micrograms of fluticasone propionate.
Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 micrograms of salmeterol as salmeterol xinafoate and 250 micrograms of fluticasone propionate.
Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 micrograms of salmeterol as salmeterol xinafoate and 500 micrograms of fluticasone propionate.
Excipients/Inactive Ingredients: Inhaler: HFA 134a.
Diskus: Lactose (which contains milk protein).